Condition

Male Breast Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 80 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials80

Recruiting1

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

ETHAN - ET for Male BCNCT05501704 · 2023-10-11

Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2NCT07558343 · 2026-10-15

NOT_YET_RECRUITING

Testosterone & Tamoxifen TrialNCT05156606 · 2022-11-10

EORTC Quality of Life Measurement in Males With Breast CancerNCT07455110 · 2019-11-01

Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast CancerNCT03018080 · 2017-06-12

Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy SpecimensNCT02480933 · 2016-09-01

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)NCT02580448 · 2015-08-01

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast CancerNCT01938833 · 2014-04-01

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast CancerNCT02060253 · 2014-04-01

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By SurgeryNCT02013492 · 2014-01-21

Understanding Male Breast Cancer: Salah Azaïz Cancer Institute ExperienceNCT03240510 · 2014-01-01

Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerNCT02046421 · 2013-11-01

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast CancerNCT01869764 · 2013-11-01

Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast CancerNCT01868503 · 2013-07-01

Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS MetastasisNCT01783756 · 2013-06-26

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyNCT01806675 · 2013-03-04

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast CancerNCT01729884 · 2012-12-01

A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS MetastasesNCT01939483 · 2012-12-01

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone TherapyNCT01720602 · 2012-11-01

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By SurgeryNCT01705340 · 2012-09-01

Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer PatientsNCT01638247 · 2012-08-01

Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast CancerNCT01632332 · 2012-07-09

Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast CancerNCT01219907 · 2012-06-01

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast CancerNCT01931709 · 2011-11-01

Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast CancerNCT01493310 · 2011-11-01

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer PatientsNCT01372579 · 2011-08-01

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast CancerNCT01394211 · 2011-07-13

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast CancerNCT01355393 · 2011-07-01

Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021).NCT01703520 · 2011-05-01

Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing ChemotherapyNCT01982591 · 2011-01-03

Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast CancerNCT01288261 · 2011-01-01

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast CancerNCT01245205 · 2010-11-01

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor TherapyNCT01153672 · 2010-11-01

Endoscopic Breast Surgery in Treating Patients With Breast CancerNCT01222377 · 2010-09-01

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast CancerNCT01104259 · 2010-07-01

RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsNCT01158274 · 2010-06-01

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsNCT01155258 · 2010-06-01

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast CancerNCT01151449 · 2010-06-01

Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast CancerNCT01084057 · 2010-05-17

Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast CancerNCT01100489 · 2010-02-01

Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast CancerNCT01042535 · 2009-12-28

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With CancerNCT01037790 · 2009-10-01

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung CancerNCT00937482 · 2009-08-01

Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast CancerNCT01706432 · 2009-06-15

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast CancerNCT00821964 · 2008-12-01

Vaccine Therapy in Treating Patients With Stage IV Breast CancerNCT00791037 · 2008-10-01

Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By SurgeryNCT00559507 · 2007-10-01

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast CancerNCT00513695 · 2007-06-01

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast CancerNCT00470301 · 2007-04-01

Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast CancerNCT00258349 · 2006-08-01

Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast CancerNCT00368875 · 2006-07-01

AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By SurgeryNCT00348699 · 2006-07-01

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast CancerNCT00331552 · 2006-02-01

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast CancerNCT00343863 · 2006-01-01

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast CancerNCT00119262 · 2005-10-01

A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)NCT00244881 · 2005-09-01

ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous TreatmentNCT00425672 · 2005-09-01

Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast CancerNCT00132002 · 2005-06-01

Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast CancerNCT00077376 · 2005-03-01

FR901228 in Treating Patients With Metastatic Breast CancerNCT00098397 · 2005-02-01

Common interventions

Leading sponsors

National Cancer Institute (NCI) 33 University of Washington 14 University of Chicago 3 University of Arizona 2 University of Southern California 2 Wake Forest University Health Sciences 2 Abramson Cancer Center at Penn Medicine 1 Case Comprehensive Cancer Center 1 Centro Hospitalar Lisboa Ocidental 1 City of Hope Medical Center 1 Fox Chase Cancer Center 1 Fred Hutchinson Cancer Center 1 GBG Forschungs GmbH 1 H. Lee Moffitt Cancer Center and Research Institute 1 Helios University Hospital Wuppertal 1

Trial status mix

COMPLETED57

TERMINATED15

UNKNOWN3

WITHDRAWN3

NOT_YET_RECRUITING1

RECRUITING1

Phase mix

PHASE242

PHASE135

NA9

EARLY_PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.